CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET. To schedule a meeting wi ...

HOLMDEL, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication, announced that it has received a $910,000 order from a long-term financial services customer to upgrade to BIO-key's "fingerprint only" Biometric Customer Identification Technology. The technology enhancem ...

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences. 2024 ThinkEqui ...

SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence ( ...

Core Viewpoint - Bio-Rad Laboratories, Inc. is set to release its third-quarter 2024 results on October 30, with expectations of mixed performance due to various market challenges and product demand dynamics [1]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for revenues in Q3 2024 is $639.9 million, reflecting a 0.8% increase from the previous year [2]. - The Zacks Consensus Estimate for EPS is $1.28, indicating a significant year-over-year decline of 45.1% [2]. - The earnings estimate has decreased by 40.2% over the past 30 days [3]. Group 2: Factors Affecting Performance - Weakness in the biotech and biopharma markets has negatively impacted sales of Life Science tools and bioprocessing products, with particular challenges in China [4]. - The process chromatography segment is expected to see a sales decline due to ongoing destocking trends in the industry [4]. - In Asia, constrained funding in Japan and soft government spending on life science research are likely to have hindered growth [4]. Group 3: Positive Developments - Despite the challenges, there is demand for the Droplet Digital PCR (ddPCR) platform, particularly in oncology and cell and gene therapy markets [5]. - The launch of new life science platforms, including the ChemiDoc Imaging Systems and a cost-effective single-cell sample prep solution, is expected to positively impact Q3 performance [5]. - The Clinical Diagnostics segment is projected to see a revenue increase of 41.9% year over year to $267.6 million, driven by demand for quality control immunohematology and blood typing products [6]. Group 4: Segment Revenue Projections - The Clinical Diagnostics segment is expected to grow, with revenues projected to increase 57.9% year over year to $369.7 million [7].

LAS VEGAS and HOLMDEL, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring phoneless, tokenless, passwordless and phish-resistant authentication solutions, announced the company will sponsor, speak, and exhibit at ISC2 Security Congress 2024, in Las Vegas on October 14 – 16, 2024. BIO-key will be hosting a session on Passkeys. Passkeys and zero trust are core enabling co ...

Core Insights - Bio-Rad Laboratories, Inc. is well-positioned in the growing digital PCR market with its QX600 Droplet Digital PCR platform, while its clinical diagnostics business is gaining momentum and expanding into new molecular diagnostics areas [1][4] - The company has faced challenges in its Biopharma segment and margin performance due to economic pressures [1][12] Group 1: Company Performance - Bio-Rad's shares have decreased by 4.8% over the past year, contrasting with the industry's growth of 24.7% and the S&P 500's rise of 33.7% [2] - The company has a market capitalization of $893.9 million and has surpassed earnings estimates in three of the last four quarters, with an average surprise of 4.1% [2] Group 2: Key Drivers - The QX600 Droplet ddPCR platform is robust and growing, with a focus on biopharma and new product development in cell biology [4] - Bio-Rad is advancing its strategy through agreements with Allegheny Health Network and Oncocyte Corporation, enhancing its clinical diagnostic applications [5] - The clinical diagnostics segment is experiencing growth, particularly in the diabetes franchise and immunohematology, with new product launches like the IH-500 instrument [6][7] Group 3: International Expansion - Bio-Rad operates in over 35 countries, with optimism about market conditions improving in late 2024 and into 2025 despite current softness in the APAC region [8][9] Group 4: Challenges - The Biopharma segment has shown weakness since 2023, linked to funding constraints in the pharmaceutical industry, impacting sales in Asia [10][11] - Economic factors such as inflation and increased costs have pressured Bio-Rad's margins, with a noted unfavorable product mix affecting gross margins [12] Group 5: Financial Estimates - The Zacks Consensus Estimate for Bio-Rad's 2024 earnings per share remains at $10.31, while revenue estimates are projected at $2.59 billion, indicating a 3% decline from the previous year [13]

MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024, in Chicago, Illinois. At booth #1165, Bio-Techne will feature its market-leading portfolio of high-quality life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions. T ...

VANCOUVER, British Columbia and HOLMDEL, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that its long-time customer, the province of British Columbia, has placed new orders with BIO-key. 10,000 users will be added to their existing deploy ...

MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate cultur ...